To include your compound in the COVID-19 Resource Center, submit it here.

Janssen submits sNDA for Invokana

Johnson & Johnson (NYSE:JNJ) submitted an sNDA to FDA for Invokana canagliflozin (JNJ-28431754, TA-7284) to

Read the full 157 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE